These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24132772)

  • 1. An open-label drug-drug interaction study of the steady-state pharmacokinetics of topiramate and glyburide in patients with type 2 diabetes mellitus.
    Manitpisitkul P; Curtin CR; Shalayda K; Wang SS; Ford L; Heald DL
    Clin Drug Investig; 2013 Dec; 33(12):929-38. PubMed ID: 24132772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic interactions between topiramate and pioglitazone and metformin.
    Manitpisitkul P; Curtin CR; Shalayda K; Wang SS; Ford L; Heald D
    Epilepsy Res; 2014 Nov; 108(9):1519-32. PubMed ID: 25219351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.
    Serra D; He YL; Bullock J; Riviere GJ; Balez S; Schwartz S; Wang Y; Ligueros-Saylan M; Jarugula V; Dole WP
    Int J Clin Pharmacol Ther; 2008 Jul; 46(7):349-64. PubMed ID: 18793589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants.
    Devineni D; Manitpisitkul P; Murphy J; Skee D; Wajs E; Mamidi RN; Tian H; Vandebosch A; Wang SS; Verhaeghe T; Stieltjes H; Usiskin K
    Clin Pharmacol Drug Dev; 2015; 4(3):226-36. PubMed ID: 27140803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects.
    Nunes T; Sicard E; Almeida L; Falcão A; Rocha JF; Brunet JS; Lefebvre M; Soares-da-Silva P
    Curr Med Res Opin; 2010 Jun; 26(6):1355-62. PubMed ID: 20377319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study.
    Rao N; Chou T; Ventura D; Abramowitz W
    Clin Ther; 2005 Oct; 27(10):1596-606. PubMed ID: 16330295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients.
    Doose DR; Brodie MJ; Wilson EA; Chadwick D; Oxbury J; Berry DJ; Schwabe S; Bialer M
    Epilepsia; 2003 Jul; 44(7):917-22. PubMed ID: 12823574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic interactions between topiramate and diltiazem, hydrochlorothiazide, or propranolol.
    Manitpisitkul P; Curtin CR; Shalayda K; Wang SS; Ford L; Heald D
    Clin Pharmacol Drug Dev; 2014 Sep; 3(5):378-87. PubMed ID: 27129011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation.
    Bialer M; Shekh-Ahmad T; Braun TL; Halvorsen MB
    Epilepsia; 2013 Aug; 54(8):1444-52. PubMed ID: 23692553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of glyburide/metformin tablets (Glucovance) versus equivalent doses of glyburide and metformin in patients with type 2 diabetes.
    Donahue SR; Turner KC; Patel S
    Clin Pharmacokinet; 2002; 41(15):1301-9. PubMed ID: 12452739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of adjunctive topiramate in infants (1-24 months) with refractory partial-onset seizures: a randomized, multicenter, open-label phase 1 study.
    Manitpisitkul P; Shalayda K; Todd M; Wang SS; Ness S; Ford L
    Epilepsia; 2013 Jan; 54(1):156-64. PubMed ID: 23157581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous topiramate: safety and pharmacokinetics following a single dose in patients with epilepsy or migraines taking oral topiramate.
    Clark AM; Kriel RL; Leppik IE; White JR; Henry TR; Brundage RC; Cloyd JC
    Epilepsia; 2013 Jun; 54(6):1106-11. PubMed ID: 23586686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects.
    Graefe-Mody U; Rose P; Ring A; Zander K; Iovino M; Woerle HJ
    Drug Metab Pharmacokinet; 2011; 26(2):123-9. PubMed ID: 21084763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy.
    Vovk T; Jakovljević MB; Kos MK; Janković SM; Mrhar A; Grabnar I
    Biol Pharm Bull; 2010; 33(7):1176-82. PubMed ID: 20606310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
    Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of topiramate pharmacokinetics and tolerability in children with epilepsy.
    Rosenfeld WE; Doose DR; Walker SA; Baldassarre JS; Reife RA
    Pediatr Neurol; 1999 May; 20(5):339-44. PubMed ID: 10371378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of oral glyburide in subjects with non-insulin-dependent diabetes mellitus and renal failure.
    Brier ME; Bays H; Sloan R; Stalker DJ; Welshman I; Aronoff GR
    Am J Kidney Dis; 1997 Jun; 29(6):907-11. PubMed ID: 9186077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers.
    Huber M; Bolbrinker J; Kreutz R
    Clin Exp Hypertens; 2006 Oct; 28(7):631-43. PubMed ID: 17060062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.